Blue Matter Hires New Partner, Jenna Riffell, Strengthening Capabilities in Europe
Prior to becoming a part of the Blue Matter team, Ms. Riffell spent nearly 10 years serving biopharmaceutical clients as a strategic consultant and leader with Kx Advisors. While there, she advanced through the consulting ranks to become a Managing Partner, building and leading Kx Advisors' European business.
While Jenna has significant expertise in the business aspects of life sciences, she also brings a robust scientific background. Before launching her consulting career, she conducted scientific research in drug development at the University of British Columbia and The Institute of Cancer Research.
Blue Matter Managing Partner, George Schmidt, said, 'Jenna brings a uniquely well-rounded background and deep expertise across areas that are critical to our clients' success. Her work spans corporate and franchise strategy, new product planning, commercial and launch strategy, and more—covering essential segments of the biopharma value chain. She also stands out as a people leader, known for mentoring teams and fostering a collaborative, high-performing environment.' Her work experience also encompasses multiple therapeutic spaces, with key focus areas being immunology, neurology, rare diseases, oncology, and women's health.
Jenna added, 'I'm excited to become a part of the Blue Matter team and begin collaborating with clients across Europe and beyond. I've been impressed by the culture at Blue Matter, which focuses on excellence but also places tremendous emphasis on building high-functioning, high-morale teams. That dynamic is a unique aspect of the firm.'
Jenna's educational background includes a Ph.D. in Biochemistry and Molecular Biology, as well as a B.Sc. (Hons) in Chemistry and Biochemistry, from the University of British Columbia.
About Blue Matter
Blue Matter (www.bluematterconsulting.com) is a strategic consulting firm serving the life sciences industry. From its offices in North America, Europe and Asia, Blue Matter serves pharmaceutical and biotech companies around the globe. The firm helps clients maximize value at the product, portfolio, and organization levels with a focus on corporate and product strategy in complex markets, as well as organizational effectiveness.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 minutes ago
- Business Wire
Flatiron Health Announces Research to Be Presented at IASLC 2025 World Conference on Lung Cancer Hosted by the International Association for the Study of Lung Cancer
NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced eight abstracts leveraging its high-quality multimodal data have been accepted for poster presentation and e-Poster presentation at the IASLC 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Barcelona, Spain. Our research at this year's WCLC exemplifies how high-quality, multimodal real-world data combined with responsible AI practices can illuminate treatment patterns, measure effectiveness, and reveal where innovation is most urgently needed. Share 'AI is a transformative force enabling scale, speed, and novel insights that were previously impossible. By harnessing advanced AI across our global network of more than five million people with cancer, we're setting a new standard for real-world data at scale,' said Nathan Hubbard, Chief Business Officer, Flatiron Health. 'Our research at this year's World Conference on Lung Cancer exemplifies how high-quality, multimodal real-world data combined with responsible AI practices can illuminate treatment patterns, measure effectiveness, and reveal where innovation is most urgently needed.' A highlight of Flatiron's presence at WCLC 2025 is the first published research leveraging the Flatiron Health–Caris Life Sciences Clinical-Molecular Database (CMDB), the largest and most robust multimodal dataset of its kind, to identify a novel gene signature that predicts risk of liver metastasis in patients with advanced non-small cell lung cancer (NSCLC). By integrating high-quality clinical data with comprehensive molecular profiling, the research addresses a critical unmet need—providing clinicians with a new tool to identify high-risk patients and potentially enable more personalized surveillance and treatment strategies. Additional highlights include: a poster highlighting ongoing gaps in biomarker testing after assessing over 13,000 patients with NSCLC in the US and UK a poster providing new insights into how NSCLC is managed in the UK, including details on the most commonly used treatments, patterns in biomarker testing, and overall survival outcomes Schedule a meeting with Flatiron Health at WCLC 2025 and follow Flatiron Health on X and LinkedIn for more updates from #WCLC25. Abstracts and Poster Presentations Partner: Caris Life Sciences Poster Session: P2.06 - Pathology and Biomarkers Presentation Number: P2.06.45 Location: Exhibit Hall Session Start/End: Monday, September 8, 10:30AM - 12PM Poster Session: P1.07 - Early-Stage Non-small Cell Lung Cancer Presentation Number: P1.07.05 Location: Exhibit Hall Session Start/End: September 7, 10:30AM - 12PM Poster Session: P3.13 - Small Cell Lung Cancer and Neuroendocrine Tumors Presentation Number: P3.13.10 Location: Exhibit Hall Session Start/End: September 9, 10 - 11:30AM Partners: Bristol-Myers Squibb, University of Colorado Cancer Center E-poster Session: EP.12 - Metastatic Non-small Cell Lung Cancer – Targeted Therapy Presentation Number: EP.12.23 Partners: Montefiore Medical Center, GSK, Rush University E-poster Session: EP.13 - Small Cell Lung Cancer and Neuroendocrine Tumors Presentation Number: EP.13.25 Partners: Lilly E-poster Session: EP.17 - Global Health, Health Services, and Health Economics Presentation Number: EP.17.33 Partners: Merck & Co E-poster Session: EP.13 - Small Cell Lung Cancer and Neuroendocrine Tumors Presentation Number: EP.13.44 About Flatiron Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.
Yahoo
31 minutes ago
- Yahoo
SnapLogic Achieves Record Quarter and Year; Founder and CEO Gaurav Dhillon Retires as Company Accelerates Growth Trajectory
Company celebrates record Q2 performance and growth of AI and agentic integration leadership SAN MATEO, Calif., August 13, 2025--(BUSINESS WIRE)--SnapLogic, the leader in agentic integration, today announced that Founder and CEO Gaurav Dhillon will retire, marking a major milestone in the company's journey. Brad Stewart, a seasoned executive with deep experience in leading and scaling high-growth technology and services businesses, has been appointed Chief Executive Officer. Dhillon, who built SnapLogic into a market success over the last decade, has transitioned to Chairman and will continue to advise the company as it builds on its strong market position. This announcement follows several key business milestones, including: Surpassed $100M+ in ARR with continued growth beyond the milestone Delivered the strongest Q2 in company history for ARR and pipeline growth Have over 21 customers with more than $1M in annual spend Over 20% of new and expansion sales tied to AI and agentic integration Processing over 5 trillion records and 1.7 billion integrations every month for thousands of customers worldwide Gaurav Dhillon, Founder and Chairman: "After building SnapLogic into a market-leading position over the last decade, I've decided it's the right time to begin a new chapter. With the company, product, and team stronger than ever, I'm proud of what we've built and excited for what comes next. It's deeply satisfying to see our pioneering strategy of leading the integration market with AI prove out." Brad Stewart, CEO: "SnapLogic is uniquely positioned at the intersection of AI, data, and enterprise automation. With a powerful platform, an impressive customer base, and a culture of innovation, I'm excited to build on Gaurav's legacy and lead the company into its next chapter." Tom Georgens, Former NetApp CEO and SnapLogic Board Member: "Gaurav is a visionary leader who saw the future of integration before anyone else and built SnapLogic into the clear leader it is today. On behalf of the Board, we thank him for his extraordinary leadership, authenticity, and impact. We're confident in SnapLogic's strong position and bright future." SnapLogic's innovation in agentic integration continues to drive measurable customer success and platform adoption. As demand accelerates, the company remains focused on helping enterprises connect, orchestrate, and scale their AI-driven initiatives through a unified AI-powered platform. About SnapLogic SnapLogic is the Agentic Integration Company, integrating AI, data, applications, and microservices into one powerful platform that transforms how enterprises connect, automate, and scale. Unlike legacy integration tools, SnapLogic is built for the AI era and trusted by global leaders, including AstraZeneca, Adobe, Verizon, and Sony. With its industry-leading platform, SnapLogic empowers every team across the enterprise to securely build faster, smarter, AI-connected workflows – all through natural language and intuitive low-code design. Join the Agentic Integration movement at Connect with SnapLogic via our Blog, X (Twitter), Facebook, or LinkedIn. View source version on Contacts Press Contacts: Gemma SmithSnapLogic Commsgsmith@ Amy McDowellOffleash PR for SnapLogicsnaplogic@ Sign in to access your portfolio
Business Wire
34 minutes ago
- Business Wire
G42 Launches OpenAI GPT-OSS Globally on Core42's AI Cloud
ABU DHABI, United Arab Emirates--(BUSINESS WIRE)-- Core42, a G42 company specializing in sovereign cloud and AI infrastructure, announced the availability of OpenAI's latest open-weight AI models, including gpt-oss-20B and gpt-oss-120B, on the Core42 AI Cloud platform, instantly accessible through the Core42 Compass API. The deployment enables enterprises, researchers, and developers to run the models on a choice of leading silicon platforms with sovereign, scalable, and high-performance capabilities. Integrated into Compass API with the flexibility to access a wide spectrum of high-performance compute platforms, Core42 delivers industry-leading inference speeds of up to 3,000 tokens per second per user, enabling real-time AI at global scale while aligning workloads with the optimal infrastructure for price-performance and scalability. This deployment delivers tailored performance for low-latency inference workloads and applications, reinforcing Core42's commitment to secure and optimized global sovereign-enabled AI infrastructure. 'Core42 AI Cloud, powered by silicon-diverse infrastructure, delivers the flexibility and performance needed for today's AI workloads,' said Kiril Evtimov, CEO of Core42 and Group CTO, G42. 'Through the Compass API, organizations can access the latest open-weight AI models and choose the optimal platform to scale transformation, optimize performance and cost, and drive progress across global markets.' Key Benefits of Core42's Open-Weight Deployment: Enterprise-scale performance – Run the fastest, most demanding workloads at global scale, enabling advanced automation, decision-making, and real-time AI experiences. Sovereign-ready scalability – Deploy high-performance AI in-country with full sovereign controls, supporting secure operations in regulated sectors such as healthcare, finance, and national security. Optimized for committed environments – Deliver fast, scalable AI in-country with sovereign controls for organizations operating under committed infrastructure agreements, ensuring predictable cost and performance. Cost-efficient agentic AI – Run agentic workloads at the lowest possible cost while maintaining in-country deployment and sovereign controls, making advanced AI accessible to cost-sensitive use cases. Available now through Compass API, these models let organizations run and adapt AI locally or in the cloud, with full transparency, fine-tuning, and sovereign deployment options. Customers can align performance, cost, and compliance to their needs. This release marks a pivotal move toward enterprise AI autonomy. With open-weight access, businesses can shape AI to their unique needs and unlock new possibilities for innovation at scale. This announcement builds on G42's recent milestones, including the unveiling of a 5GW US-UAE AI campus and the launch of the 1GW Stargate UAE facility as Phase 1 of the project, as well as a $1.5 billion investment from Microsoft in 2024, reinforcing the UAE's role as a global AI hub. For more information, visit and About Core42 Core42, a G42 company, empowers individuals, enterprises, and nations to unlock the full potential of AI through its comprehensive enablement capabilities. As a leading provider of sovereign cloud, AI infrastructure, and services, our mission is to accelerate the achievements of others and help them reach their most ambitious goals. To learn more, please visit and follow Core42 LinkedIn, Core42 Instagram, Core42 X About G42 G42 is a global leader in creating visionary artificial intelligence capabilities for a better tomorrow. Born in Abu Dhabi and operating around the world, G42 champions AI as a powerful force for good. Its people are constantly reimagining what technology can do, applying advanced thinking and innovation to accelerate progress and tackle society's most pressing problems. G42 is joining forces with nations, corporations and individuals to create the infrastructure for tomorrow's world. From molecular biology to space exploration and everything in between, G42 realizes exponential possibilities, today. For further information visit Source: AETOSWire
